These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 23778032)

  • 1. Effect of omega-3 fatty acids for indicated prevention of young patients at risk for psychosis: when do they begin to be effective?
    Mossaheb N; Schäfer MR; Schlögelhofer M; Klier CM; Cotton SM; McGorry PD; Amminger GP
    Schizophr Res; 2013 Aug; 148(1-3):163-7. PubMed ID: 23778032
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial.
    Amminger GP; Schäfer MR; Papageorgiou K; Klier CM; Cotton SM; Harrigan SM; Mackinnon A; McGorry PD; Berger GE
    Arch Gen Psychiatry; 2010 Feb; 67(2):146-54. PubMed ID: 20124114
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Omega-3 fatty acid supplementation in adolescents with borderline personality disorder and ultra-high risk criteria for psychosis: a post hoc subgroup analysis of a double-blind, randomized controlled trial.
    Amminger GP; Chanen AM; Ohmann S; Klier CM; Mossaheb N; Bechdolf A; Nelson B; Thompson A; McGorry PD; Yung AR; Schäfer MR
    Can J Psychiatry; 2013 Jul; 58(7):402-8. PubMed ID: 23870722
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomised, double-blind, placebo-controlled trial of minocycline and/or omega-3 fatty acids added to treatment as usual for at-risk mental states (NAYAB): study protocol.
    Qurashi I; Chaudhry IB; Khoso AB; Farooque S; Lane S; Husain MO; Chu S; Sarginson J; Hamarani M; Naqvi HA; Razzaque B; Minhas FA; Yung AR; Deakin JFW; Husain N
    Trials; 2017 Nov; 18(1):524. PubMed ID: 29121974
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NEURAPRO-E study protocol: a multicentre randomized controlled trial of omega-3 fatty acids and cognitive-behavioural case management for patients at ultra high risk of schizophrenia and other psychotic disorders.
    Markulev C; McGorry PD; Nelson B; Yuen HP; Schaefer M; Yung AR; Thompson A; Berger G; Mossaheb N; Schlögelhofer M; Smesny S; de Haan L; Riecher-Rössler A; Nordentoft M; Chen EYH; Verma S; Hickie I; Amminger GP
    Early Interv Psychiatry; 2017 Oct; 11(5):418-428. PubMed ID: 26279065
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of ω-3 Polyunsaturated Fatty Acids in Young People at Ultrahigh Risk for Psychotic Disorders: The NEURAPRO Randomized Clinical Trial.
    McGorry PD; Nelson B; Markulev C; Yuen HP; Schäfer MR; Mossaheb N; Schlögelhofer M; Smesny S; Hickie IB; Berger GE; Chen EY; de Haan L; Nieman DH; Nordentoft M; Riecher-Rössler A; Verma S; Thompson A; Yung AR; Amminger GP
    JAMA Psychiatry; 2017 Jan; 74(1):19-27. PubMed ID: 27893018
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Frontal delta power associated with negative symptoms in ultra-high risk individuals who transitioned to psychosis.
    Lavoie S; Schäfer MR; Whitford TJ; Benninger F; Feucht M; Klier CM; Yuen HP; Pantelis C; McGorry PD; Amminger GP
    Schizophr Res; 2012 Jul; 138(2-3):206-11. PubMed ID: 22520856
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors of longer-term outcome in the Vienna omega-3 high-risk study.
    Mossaheb N; Schäfer MR; Schlögelhofer M; Klier CM; Smesny S; McGorry PD; Berger M; Amminger GP
    Schizophr Res; 2018 Mar; 193():168-172. PubMed ID: 28823721
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Indicated prevention with long-chain polyunsaturated omega-3 fatty acids in patients with 22q11DS genetically at high risk for psychosis. Protocol of a randomized, double-blind, placebo-controlled treatment trial.
    Armando M; De Crescenzo F; Vicari S; Digilio MC; Pontillo M; Papaleo F; Amminger GP
    Early Interv Psychiatry; 2016 Oct; 10(5):390-6. PubMed ID: 25345540
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of omega-3 PUFA on immune markers in adolescent individuals at ultra-high risk for psychosis - Results of the randomized controlled Vienna omega-3 study.
    Smesny S; Milleit B; Schaefer MR; Hesse J; Schlögelhofer M; Langbein K; Hipler UC; Berger M; Cotter DR; Sauer H; McGorry PD; Amminger GP
    Schizophr Res; 2017 Oct; 188():110-117. PubMed ID: 28126360
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictors of treatment response in young people at ultra-high risk for psychosis who received long-chain omega-3 fatty acids.
    Amminger GP; Mechelli A; Rice S; Kim SW; Klier CM; McNamara RK; Berk M; McGorry PD; Schäfer MR
    Transl Psychiatry; 2015 Jan; 5(1):e495. PubMed ID: 25585167
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Early detection of psychotic disorders].
    Schäfer MR; Klier CM; Papageorgiou K; Friedrich MH; Amminger GP
    Neuropsychiatr; 2007; 21(1):37-44. PubMed ID: 17555006
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Omega-3 fatty acid supplementation changes intracellular phospholipase A2 activity and membrane fatty acid profiles in individuals at ultra-high risk for psychosis.
    Smesny S; Milleit B; Hipler UC; Milleit C; Schäfer MR; Klier CM; Holub M; Holzer I; Berger GE; Otto M; Nenadic I; Berk M; McGorry PD; Sauer H; Amminger GP
    Mol Psychiatry; 2014 Mar; 19(3):317-24. PubMed ID: 23478748
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changes in triglyceride levels in ultra-high risk for psychosis individuals treated with omega-3 fatty acids.
    Mossaheb N; Papageorgiou K; Schäfer MR; Becker J; Schloegelhofer M; Amminger GP
    Early Interv Psychiatry; 2018 Feb; 12(1):30-36. PubMed ID: 26362578
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Longer-term outcome in the prevention of psychotic disorders by the Vienna omega-3 study.
    Amminger GP; Schäfer MR; Schlögelhofer M; Klier CM; McGorry PD
    Nat Commun; 2015 Aug; 6():7934. PubMed ID: 26263244
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship between Erythrocyte Fatty Acid Composition and Psychopathology in the Vienna Omega-3 Study.
    Kim SW; Jhon M; Kim JM; Smesny S; Rice S; Berk M; Klier CM; McGorry PD; Schäfer MR; Amminger GP
    PLoS One; 2016; 11(3):e0151417. PubMed ID: 26963912
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized controlled trial of interventions for young people at ultra-high risk of psychosis: twelve-month outcome.
    McGorry PD; Nelson B; Phillips LJ; Yuen HP; Francey SM; Thampi A; Berger GE; Amminger GP; Simmons MB; Kelly D; Dip G; Thompson AD; Yung AR
    J Clin Psychiatry; 2013 Apr; 74(4):349-56. PubMed ID: 23218022
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A potential role for adjunctive omega-3 polyunsaturated fatty acids for depression and anxiety symptoms in recent onset psychosis: Results from a 16 week randomized placebo-controlled trial for participants concurrently treated with risperidone.
    Robinson DG; Gallego JA; John M; Hanna LA; Zhang JP; Birnbaum ML; Greenberg J; Naraine M; Peters BD; McNamara RK; Malhotra AK; Szeszko PR
    Schizophr Res; 2019 Feb; 204():295-303. PubMed ID: 30241990
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of omega-3 PUFA on the vitamin E and glutathione antioxidant defense system in individuals at ultra-high risk of psychosis.
    Smesny S; Milleit B; Schaefer MR; Hipler UC; Milleit C; Wiegand C; Hesse J; Klier CM; Holub M; Holzer I; Berk M; McGorry PD; Sauer H; Amminger GP
    Prostaglandins Leukot Essent Fatty Acids; 2015 Oct; 101():15-21. PubMed ID: 26260538
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized placebo-controlled trial of an omega-3 fatty acid and vitamins E+C in schizophrenia.
    Bentsen H; Osnes K; Refsum H; Solberg DK; Bøhmer T
    Transl Psychiatry; 2013 Dec; 3(12):e335. PubMed ID: 24346133
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.